Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the future

Journal of Allergy and Clinical Immunology

Volumn 137, Issue 2, 2016, Pages 351-357

  Valenta, Rudolf ^a   Campana, Raffaela ^a   Focke Tejkl, Margit ^a   Niederberger, Verena ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

allergen; allergen specific immunotherapy; Allergy; allergy vaccine; preventive allergy vaccine

Indexed keywords

ALLERGEN; EPITOPE; IMMUNOGLOBULIN G ANTIBODY; RECOMBINANT ALLERGEN; RECOMBINANT VACCINE; SYNTHETIC PEPTIDE; VENOM; IMMUNOGLOBULIN E; PEPTIDE;

ALLERGEN SPECIFIC IMMUNOTHERAPY; ALLERGY; B LYMPHOCYTE; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); FOOD; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; VACCINATION; ADVERSE EFFECTS; CHEMISTRY; DESENSITIZATION; HYPERSENSITIVITY; IMMUNOLOGY; PROCEDURES; STANDARDS;

ALLERGENS; DESENSITIZATION, IMMUNOLOGIC; EPITOPES, B-LYMPHOCYTE; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; PEPTIDES; VACCINES, SYNTHETIC;

EID: 84957941850     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2015.12.1299     Document Type: Article

References (79)

1. L. Noon Prophylactic inoculation against hay fever Lancet 1 1911 1572 1573
2. W.P. Dunbar Zur Frage betreffend die Ätiologie und spezifische Therapie des Heufiebers. Berliner klin Wochenschr 1903 24 26
3. R.A. Cooke, J.H. Barnard, S. Hebald, and A. Stull Serological evidence of immunity coexisting sensitization in a type of human allergy (hay fever) J Exp Med 62 1935 733 750
4. M. Larche, C.A. Akdis, and R. Valenta Immunological mechanisms of allergen-specific immunotherapy Nat Rev Immunol 6 2006 761 771
5. J. Bousquet, R. Lockey, and H.J. Malling Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper J Allergy Clin Immunol 102 1998 558 562
6. M. Jutel, I. Agache, S. Bonini, A.W. Burks, M. Calderon, W. Canonica, and et al. International consensus on allergy immunotherapy J Allergy Clin Immunol 136 2015 556 568
7. L. Cox, M. Calderón, and O. Pfaar Subcutaneous allergen immunotherapy for allergic disease: examining efficacy, safety and cost-effectiveness of current and novel formulations Immunotherapy 4 2012 601 616
8. L. Jacobsen, B. Niggemann, S. Dreborg, H.A. Ferdousi, S. Halken, A. Host, and et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study Allergy 62 2007 943 948
9. E. Valovirta Effect of AIT in children including potential to prevent the development of asthma Allergy 66 suppl 95 2011 53 54
10. S.R. Durham, S.M. Walker, E.M. Varga, M.R. Jacobson, F. O'Brien, W. Noble, and et al. Long-term clinical efficacy of grass-pollen immunotherapy N Engl J Med 341 1999 468 475
11. L.K. James, M.H. Shamji, S.M. Walker, D. Wilson, P.A. Wachholz, J.N. Francis, and et al. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies J Allergy Clin Immunol 127 2011 509 516
12. N. Mothes, M. Heinzkill, K.J. Drachenberg, W.R. Sperr, M.T. Krauth, Y. Majlesi, and et al. Allergen-specific immunotherapy with monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies Clin Exp Allergy 33 2003 1198 1208
13. V. Niederberger, F. Horak, S. Vrtala, S. Spitzauer, M.T. Krauth, P. Valent, and et al. Vaccination with genetically engineered allergens prevents progression of allergic disease Proc Natl Acad Sci U S A 101 suppl 2 2004 14677 14682
14. P.S. Creticos, J.T. Schroeder, R.G. Hamilton, S.L. Balcer-Whaley, A.P. Khattignavong, R. Lindblad, and et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis N Engl J Med 355 2006 1445 1455
15. R. Hiller, S. Laffer, C. Harwanegg, M. Huber, W.M. Schmidt, A. Twardosz, and et al. Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment FASEB J 16 2002 414 416
16. C. Lupinek, E. Wollmann, A. Baar, S. Banerjee, H. Breiteneder, B.M. Broecker, and et al. Advances in allergen-microarray technology for diagnosis and monitoring of allergy: the MeDALL allergen-chip Methods 66 2014 106 119
17. G.W. Canonica, I.L. Ansotequi, R. Pawankar, P. Schmid-Grendelmeier, M. van Hage, C.E. Baena-Cagnani, and et al. A WAO-ARIA-GA2LEN consensus document on molecular-based allergy diagnostics World Allergy Organ J 6 2013 17
18. J. Sastre, M.E. Landivar, M. Ruiz-García, M.V. Andregnette-Rosigno, and I. Mahillo How molecular diagnosis can change allergen-specific immunotherapy prescription in a complex pollen area Allergy 67 2012 709 711
19. E. Wollmann, C. Lupinek, M. Kundi, R. Selb, V. Niederberger, and R. Valenta Reduction in allergen-specific IgE binding as measured by microarray: a possible surrogate marker for effects of specific-immunotherapy J Allergy Clin Immunol 136 2015 806 809
20. L. Winther, J. Arnved, H.J. Malling, H. Nolte, and H. Mosbech Side-effects of allergen-specific immunotherapy: a prospective multi-centre study Clin Exp Allergy 36 2006 254 260
21. R.F. Sledge Treatment of hay-fever with alum-precipitated pollen extract U S Naval Bull 36 1938 18 29
22. D.G. Marsh, L.M. Lichtenstein, and D.H. Campbell Studies on "allergoids" prepared from naturally occurring allergens. I. Assay of allergenicity and antigenicity of formalinized rye group I component Immunology 18 1970 705 722
23. B.M. Haselden, A.B. Kay, and M. Larché Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions J Exp Med 189 1999 1885 1894
24. P.S. Norman, L.M. Lichtenstein, and D.G. Marsh Studies on allergoids from naturally occurring allergens. IV. Efficacy and safety of long-term allergoid treatment of ragweed hay fever J Allergy Clin Immunol 68 1981 460 470
25. J. Bousquet, A. Hejjaouim, M. Soussana, and F.B. Michel Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. IV. Comparison of safety and efficacy of two dosages of a high-molecular-weight allergoid J Allergy Clin Immunol 85 1990 490 497
26. H. Kahlert, E. Grage-Griebenow, H.T. Stüwe, O. Cromwell, and H. Fiebig T cell reactivity with allergoids: influence of the type of APC J Immunol 165 2000 1807 1815
27. S. von Moos, P. Johansen, F. Tay, N. Graf, T.M. Kündig, and G. Senti Comparing safety of abrasion and tape-stripping as skin preparation in allergen-specific epicutaneous immunotherapy J Allergy Clin Immunol 134 2014 965 967
28. L. Spina, M. Weisskopf, S. von Moos, N. Graf, T.M. Kündig, and G. Senti Comparison of microneedles and adhesive-tape stripping in skin preparation for epicutaneous allergen delivery Int Arch Allergy Immunol 167 2015 103 109
29. S. Sato, N. Yanagida, K. Ogura, T. Imai, T. Utsunomiya, K. Iikura, and et al. Clinical studies in oral allergen-specific immunotherapy: differences among allergens Int Arch Allergy Immunol 164 2014 1 9
30. S.R. Durham, W.H. Yang, M.R. Pedersen, N. Johansen, and S. Rak Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis J Allergy Clin Immunol 117 2006 802 809
31. M.A. Keil, E. Röder, R. Gerth van Wijk, M.J. Al, W.C. Hop, and M.P. Rutten-van Mölken Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy J Allergy Clin Immunol 132 2013 353 360
32. M. Focke, K. Marth, S. Flicker, and R. Valenta Heterogeneity of commercial timothy grass pollen extracts Clin Exp Allergy 38 2008 1400 1408
33. A. Casset, A. Mari, A. Purohit, I. Resch, M. Weghofer, R. Ferrara, and et al. Varying allergen composition and content affects the in vivo allergenic activity of commercial Dermatophagoides pteronyssinus extracts Int Arch Allergy Immunol 159 2012 253 262
34. A. Casset, R. Valenta, and S. Vrtala Allergen content and allergenic activity of house dust mite extracts Int Arch Allergy Immunol 161 2013 287 288
35. B. Linhart, B. Jahn-Schmid, P. Verdino, W. Keller, C. Ebner, D. Kraft, and et al. Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity FASEB J 16 2002 1301 1303
36. E. Gadermaier, J. Staikuniene, S. Scheiblhofer, J. Thalhamer, M. Kundi, K. Westritschnig, and et al. Recombinant allergen-based monitoring of antibody responses during injection grass pollen immunotherapy and after 5 years of discontinuation Allergy 66 2011 1174 1182
37. M. Focke, I. Swoboda, K. Marth, and R. Valenta Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity Clin Exp Allergy 40 2010 385 397
38. 2LEN joint paper Int Arch Allergy Immunol 161 2013 1 10
39. M. Westman, C. Lupinek, J. Bousquet, N. Andersson, S. Pahr, A. Baar, and et al. Early childhood IgE reactivity to pathogenesis-related class 10 proteins predicts allergic rhinitis in adolescence J Allergy Clin Immunol 135 2015 1199 1206
40. A. Asarnoj, C. Hamsten, K. Wadén, C. Lupinek, N. Andersson, I. Kull, and et al. Sensitization to cat and dog allergen molecules in childhood and prediction of symptoms of cat and dog allergy in adolescence: a Barn/Children Allergy/Asthma Milieu Stockholm Epidemiologic (BAMSE) mechanisms for the development of allergy study J Allergy Clin Immunol 2015 [E-pub ahead of print]
41. A. Custovic, H.J. Sonntag, I.E. Buchan, D. Belgrave, A. Simpson, M.C. Prosperi, and et al. Evolution pathways of IgE responses to grass and mite allergens throughout childhood J Allergy Clin Immunol 136 2015 1645 1652.e8
42. R. Valenta, R. Campana, K. Marth, and M. van Hage Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches J Intern Med 272 2012 144 157
43. Z. Szépfalusi, C. Bannert, L. Ronceray, E. Mayer, M. Hassler, E. Wissmann, and et al. Preventive sublingual immunotherapy in preschool children: first evidence for safety and pro-tolerogenic effects J Allergy Clin Immunol 25 2014 788 795
44. Z. Zolkipli, G. Roberts, V. Cornelius, B. Clayton, S. Pearson, L. Michaelis, and et al. Randomized controlled trial of primary prevention of atopy using house dust mite allergen oral immunotherapy in early childhood J Allergy Clin Immunol 136 2015 1541 1547.e11
45. G. Du Toit, G. Roberts, P.H. Sayre, H.T. Bahnson, S. Radulovic, A.F. Santos, and et al. Randomized trial of peanut consumption in infants at risk for peanut allergy N Engl J Med 372 2015 803 813
46. B. Linhart, A. Hartl, B. Jahn-Schmid, P. Verdino, W. Keller, M.T. Krauth, and et al. A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination J Allergy Clin Immunol 115 2005 1010 1016
47. G. Pauli, T.H. Larsen, S. Rak, F. Horak, E. Pastorello, R. Valenta, and et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis J Allergy Clin Immunol 122 2008 951 960
48. E. Nony, J. Bouley, M. Le Mignon, P. Lemoine, K. Jain, S. Horiot, and et al. Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen-allergic patients Allergy 70 2015 795 804
49. M. Jutel, L. Jaeger, R. Suck, H. Meyer, H. Fiebig, and O. Cromwell Allergen-specific immunotherapy with recombinant grass pollen allergens J Allergy Clin Immunol 116 2005 608 613
50. L. Klimek, P. Schendzielorz, R. Pinol, and O. Pfaar Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study Clin Exp Allergy 42 2012 936 945
51. B. Linhart, and R. Valenta Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives Vaccine 30 2012 4328 4335
52. A. Purohit, V. Niederberger, M. Kronqvist, F. Horak, R. Grönneberg, R. Suck, and et al. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives Clin Exp Allergy 38 2008 1514 1525
53. R. Campana, S. Vrtala, B. Maderegger, P. Jertschin, G. Stegfellner, I. Swoboda, and et al. Hypoallergenic derivatives of the major birch pollen allergen Bet v 1 obtained by rational sequence reassembly J Allergy Clin Immunol 126 2010 1024 1031
54. R. Campana, K. Moritz, K. Marth, A. Neubauer, H. Huber, R. Henning, and et al. Frequent occurrence of T cell-mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments J Allergy Clin Immunol 137 2016 601 609
55. F. Spertini, Y. Perrin, R. Audran, C. Pellaton, C. Boudousquié, N. Barbier, and et al. Safety and immunogenicity of immunotherapy with Bet v 1-derived contiguous overlapping peptides J Allergy Clin Immunol 134 2014 239 240
56. L. Klimek, C. Bachert, K.F. Lukat, O. Pfaar, H. Meyer, and A. Narkus Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v. 1-FV in a randomized controlled trial Clin Transl Allergy 5 2015 28
57. G. Senti, R. Crameri, D. Kuster, P. Johansen, J.M. Martinez-Gomez, N. Graf, and et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections J Allergy Clin Immunol 129 2012 1290 1296
58. A. Zaleska, T. Eiwegger, O. Soyer, W. van de Veen, C. Rhyner, M.B. Soyka, and et al. Immune regulation by intralymphatic immunotherapy with modular allergen translocation MAT vaccine Allergy 69 2014 1162 1170
59. I. Swoboda, A. Bugajska-Schretter, B. Linhart, P. Verdino, W. Keller, U. Schulmeister, and et al. A recombinant hypoallergenic parvalbumin mutant for immunotherapy of IgE-mediated fish allergy J Immunol 178 2007 6290 6296
60. N. Douladiris, B. Linhart, I. Swoboda, A. Gstöttner, E. Vassilopoulou, F. Stolz, and et al. In vivo allergenic activity of a hypoallergenic mutant of the major fish allergen Cyp c 1 evaluated by means of skin testing J Allergy Clin Immunol 136 2015 493 495
61. L. Zuidmeer-Jongejan, H. Huber, I. Swoboda, N. Rigby, S.A. Versteeg, B.M. Jensen, and et al. Development of a hypoallergenic recombinant parvalbumin for first-in-man subcutaneous immunotherapy of fish allergy Int Arch Allergy Immunol 166 2015 41 51
62. B. Linhart, M. Focke-Tejkl, M. Weber, M. Narayanan, A. Neubauer, H. Mayrhofer, and et al. Molecular evolution of hypoallergenic hybrid proteins for vaccination against grass pollen allergy J Immunol 194 2015 4008 4018
63. K.W. Chen, K. Blatt, W.R. Thomas, I. Swoboda, P. Valent, R. Valenta, and et al. Hypoallergenic Der p 1/Der p 2 combination vaccines for immunotherapy of house dust mite allergy J Allergy Clin Immunol 130 2012 435 443
64. M. Worm, H.H. Lee, J. Kleine-Tebbe, R.P. Hafner, P. Laidler, D. Healey, and et al. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy J Allergy Clin Immunol 127 2011 89 97
65. D. Patel, P. Couroux, P. Hickey, A.M. Salapatek, P. Laidler, M. Larché, and et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study J Allergy Clin Immunol 131 2013 103 109
66. P. Couroux, D. Patel, K. Armstrong, M. Larché, and R.P. Hafner Fel d 1-derived synthetic peptide immuno-regulatory epitopes show a long-term treatment effect in cat allergic subjects Clin Exp Allergy 45 2015 974 981
67. R. Valenta, S. Vrtala, M. Focke-Tejkl, Bugajska-Schretter, T. Ball, A. Twardosz, and et al. Genetically engineered and synthetic allergen derivatives: candidates for vaccination against type I allergy Biol Chem 380 1999 815 824
68. M. Focke, V. Mahler, T. Ball, W.R. Sperr, Y. Majlesi, P. Valent, and et al. Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination FASEB J 15 2001 2042 2044
69. M. Focke, B. Linhart, A. Hartl, U. Wiedermann, W.R. Sperr, P. Valent, and et al. Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination Clin Exp Allergy 34 2004 1525 1533
70. M. Focke-Tejkl, M. Weber, K. Niespodziana, A. Neubauer, H. Huber, R. Henning, and et al. Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy J Allergy Clin Immunol 135 2015 1207 1217 e1-11
71. V. Niederberger, K. Marth, J. Eckl-Dorna, M. Focke-Tejkl, M. Weber, W. Hemmer, and et al. Skin test evaluation of a novel peptide carrier-based vaccine, BM32, in grass pollen-allergic patients J Allergy Clin Immunol 136 2015 1101 1103
72. T.M. Kündig, G. Senti, G. Schnetzler, C. Wolf, B.M. Prinz Vavricka, A. Fulurija, and et al. Der p 1 peptide on virus-like particles is safe and highly immunogenic in health adults J Allergy Clin Immunol 117 2006 1470 1476
73. N. Schmitz, K. Dietmeier, M. Bauer, M. Maudrich, S. Utzinger, S. Muntwiler, and et al. Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy J Exp Med 206 2009 1941 1945
74. J. Edlmayr, K. Niespodziana, B. Linhart, M. Focke-Teijkl, K. Westritschnig, S. Schiblhofer, and et al. A combination vaccine for allergy and rhinovirus infections based on rhinovirus-derived surface protein VP1 and nonallergenic peptide of the major timothy grass pollen allergen Phl p 1 J Immunol 182 2009 6298 6306
75. K. Niespodziana, M. Focke-Tejkl, B. Linhart, V. Civaj, K. Blatt, P. Valent, and et al. A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS J Allergy Clin Immunol 127 2011 1562 1570
76. J. Edlmayr, K. Niespodziana, M. Focke-Tejkl, B. Linhart, and R. Valenta Allergen-specific immunotherapy: towards combination vaccines for allergic and infectious diseases Curr Top Microbiol Immunol 352 2011 121 140
77. K. Marth, I. Breyer, M. Focke-Tejkl, K. Blatt, M.H. Shamji, J. Layhadi, and et al. A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to an tolerogenic and Th1 phenotype J Immunol 190 2013 3068 3078
78. S. Banerjee, M. Weber, K. Blatt, I. Swoboda, M. Focke-Tejkl, P. Valent, and et al. Conversion of Der p 23, a new major house dust mite allergen, into a hypoallergenic vaccine J Immunol 192 2014 4867 4875
79. B. Linhart, M. Narayanan, M. Focke-Tejkl, F. Wrba, S. Vrtala, and R. Valenta Prophylactic and therapeutic vaccination with carrier-bound Bet v 1 peptides lacking allergen-specific T cell epitopes reduces Bet v 1-specific T cell responses via blocking antibodies in a murine model for birch pollen allergy Clin Exp Allergy 44 2014 278 287